Anagrelide Cancer Patent For Japan
Filed with ASX · · 2 pages · English
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- SUDA Signs Additional Licence With Mitsubishi Tanabe
- Half Yearly Report and Accounts
- SANOFI and SUDA Entered Into A Feasibility Agreement
- SUDA Signs Co-Development Deal With Ordesa
- SUDA Appoints Dr Michael Baker CEO
Later from Arovella Therapeutics
- Suspension from Official Quotation
- Market Update
- Entitlement Offer To Raise Approximately $3.56 Million
- Prospectus For Entitlement Offer
- TGA Approval Granted For ZolpiMist
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics